<DOC>
	<DOCNO>NCT00678418</DOCNO>
	<brief_summary>This Phase 3 multi-center trial design evaluate clinical efficacy safety VIVITROL速 ( Medisorb速 naltrexone 380 mg ) versus placebo administer adult upon discharge inpatient treatment opioid dependence . The study conduct 2 part , Part A Part B . The clinical portion part complete . Results Part B yet available .</brief_summary>
	<brief_title>ALK21-013 : Efficacy Safety Medisorb速 Naltrexone ( VIVITROL速 ) Adults With Opioid Dependence</brief_title>
	<detailed_description>Part A double-blind , randomize , placebo-controlled assessment efficacy safety 24 week monthly treatment VIVITROL compare placebo opioid-dependent adult . Subjects complete Part A could choose continue Part B , open-label extension ass longer-term safety , durability effect , health economics , quality life ( QOL ) continue study population 1 year . At conclusion part , complete subject receive total 19 injection study drug approximately 1.5 year . Dosing perform principal investigator designate study staff member . All subject receive standardized , manual-based psychosocial support schedule visit . Opioid use track urine drug test subject ' self report . Other evaluation efficacy safety , health economics , quality life routinely conduct throughout study .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Written , inform consent 18 year age old Current diagnosis opioid dependence , base Diagnostic Statistical Manual Mental Health Disorders , 4th Ed . ( DSMIVTR ) criteria Voluntarily seek treatment opioid dependence Completing recently complete 30 day inpatient treatment opioid detoxification , opioids ( include buprenorphine methadone ) least 7 day Noncustodial , stable residence phone , plus 1 contact verifiable address phone Significant ( eg , spouse , relative ) willing supervise compliance study visit schedule procedure Agree use contraception study duration childbearing potential Primary Pregnancy lactation Clinically significant medical condition observe abnormality ( eg : physical exam , electrocardiogram ( ECG ) , lab and/or urinalysis finding ) Positive naloxone challenge test randomization ( Day 0 ) Evidence hepatic failure include : ascites , bilirubin &gt; 10 % upper limit normal ( ULN ) and/or esophageal variceal disease Past present history acquire immunodeficiency syndrome ( AIDS ) indicator disease HIVinfected subject Active hepatitis and/or aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 3xULN Current major depression suicidal ideation , psychosis , bipolar disorder , psychiatric disorder would compromise ability complete study Recent history ( within 6 month prior screen ) suicidal ideation attempt Dependence within prior year base DSMIVTR , drug prescription opioids heroin , caffeine , marijuana , nicotine Active alcohol dependence within prior 6 month Current alcohol use disorder would , Investigator 's opinion , preclude successful completion study Positive urine drug test cocaine , benzodiazepine , amphetamine screen Use oral naltrexone 7 consecutive day within 60 day prior screen Known intolerance and/or hypersensitivity naltrexone , carboxymethylcellulose , polylactidecoglycolide ( PLG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Addiction</keyword>
	<keyword>Opiate dependence</keyword>
	<keyword>Inpatient detoxification</keyword>
	<keyword>opioid dependence</keyword>
	<keyword>heroin dependence</keyword>
</DOC>